Reviewing Biotricity (NASDAQ:BTCY) & H-CYTE (OTCMKTS:HCYTD)

Biotricity (NASDAQ:BTCY) and H-CYTE (OTCMKTS:HCYTD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends and earnings.

Volatility & Risk

Biotricity has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500. Comparatively, H-CYTE has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500.

Institutional and Insider Ownership

3.9% of Biotricity shares are held by institutional investors. 10.1% of Biotricity shares are held by insiders. Comparatively, 5.2% of H-CYTE shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent recommendations for Biotricity and H-CYTE, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biotricity	0	1	0	0	2.00
H-CYTE	0	0	0	0	0.00

Profitability

This table compares Biotricity and H-CYTE’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biotricity	-80.42%	N/A	-188.47%
H-CYTE	-450.40%	N/A	-777.68%

Valuation & Earnings

This table compares Biotricity and H-CYTE”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biotricity	$12.06 million	1.20	-$14.09 million	($0.21)	-2.57
H-CYTE	$1.61 million	0.32	-$4.80 million	N/A	N/A

H-CYTE has lower revenue, but higher earnings than Biotricity.

Summary

Biotricity beats H-CYTE on 8 of the 9 factors compared between the two stocks.

About Biotricity

Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.

About H-CYTE

H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.